Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia

Schizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Soares, Bruno Lobão, Oliveira, João Paulo Maia de, Machado-de-Sousa, João Paulo, Baker, Glen B., Dursun, Serdar, Hallak, Jaime E. C.
Formato: article
Idioma:eng
Publicado em: Associação Brasileira de Psiquiatria
Assuntos:
Schizophrenia
Endereço do item:https://repositorio.ufrn.br/jspui/handle/123456789/25437
http://dx.doi.org/10.1590/S1516-44462011000300003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
id ri-123456789-25437
record_format dspace
spelling ri-123456789-254372021-11-11T18:35:33Z Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia A via receptor NMDA-óxido nítrico-GMP cíclico como alvo para o desenvolvimento de medicações antipsicóticas não-dopaminérgicas para a esquizofrenia Soares, Bruno Lobão Oliveira, João Paulo Maia de Machado-de-Sousa, João Paulo Baker, Glen B. Dursun, Serdar Hallak, Jaime E. C. Schizophrenia Schizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in schizophrenia patients. Recent evidence suggests that dopaminergic abnormalities may be secondary to dysfunctions in multi-neurotransmitter systems modulating dopamine. One of the key neurotransmitters thought to be involved in schizophrenia is glutamate, and there is strong support for the involvement of a hypoactivity of N-methyl-D-aspartate (NMDA) glutamate receptors in the pathogenesis of schizophrenia. However, research with NMDA receptor agonists for the treatment of schizophrenia has produced inconsistent results, which may be due to the development of rapid tolerance to these compounds secondary to down-regulation of NMDA receptors. Perhaps the development of drugs that act on targets downstream NMDA receptors, such as nitric oxide (NO), could avoid the problem of the down-regulation of these receptors. 2018-06-16T15:43:29Z 2018-06-16T15:43:29Z 2011-09 article SOARES, Bruno Lobão et al.Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia. Revista Brasileira de Psiquiatria, v. 33, p. 223-224, 2011. Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462011000300003&lng=en&tlng=en>. Acesso em: 23 mar. 2018. 1809-452X https://repositorio.ufrn.br/jspui/handle/123456789/25437 http://dx.doi.org/10.1590/S1516-44462011000300003 eng Acesso Aberto application/pdf Associação Brasileira de Psiquiatria
institution Repositório Institucional
collection RI - UFRN
language eng
topic Schizophrenia
spellingShingle Schizophrenia
Soares, Bruno Lobão
Oliveira, João Paulo Maia de
Machado-de-Sousa, João Paulo
Baker, Glen B.
Dursun, Serdar
Hallak, Jaime E. C.
Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
description Schizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in schizophrenia patients. Recent evidence suggests that dopaminergic abnormalities may be secondary to dysfunctions in multi-neurotransmitter systems modulating dopamine. One of the key neurotransmitters thought to be involved in schizophrenia is glutamate, and there is strong support for the involvement of a hypoactivity of N-methyl-D-aspartate (NMDA) glutamate receptors in the pathogenesis of schizophrenia. However, research with NMDA receptor agonists for the treatment of schizophrenia has produced inconsistent results, which may be due to the development of rapid tolerance to these compounds secondary to down-regulation of NMDA receptors. Perhaps the development of drugs that act on targets downstream NMDA receptors, such as nitric oxide (NO), could avoid the problem of the down-regulation of these receptors.
format article
author Soares, Bruno Lobão
Oliveira, João Paulo Maia de
Machado-de-Sousa, João Paulo
Baker, Glen B.
Dursun, Serdar
Hallak, Jaime E. C.
author_facet Soares, Bruno Lobão
Oliveira, João Paulo Maia de
Machado-de-Sousa, João Paulo
Baker, Glen B.
Dursun, Serdar
Hallak, Jaime E. C.
author_sort Soares, Bruno Lobão
title Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
title_short Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
title_full Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
title_fullStr Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
title_full_unstemmed Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
title_sort targeting the nmda receptor-nitric oxide-cyclic gmp pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
publisher Associação Brasileira de Psiquiatria
publishDate 2018
url https://repositorio.ufrn.br/jspui/handle/123456789/25437
http://dx.doi.org/10.1590/S1516-44462011000300003
work_keys_str_mv AT soaresbrunolobao targetingthenmdareceptornitricoxidecyclicgmppathwaytodevelopnondopaminergicantipsychoticmedicationsforschizophrenia
AT oliveirajoaopaulomaiade targetingthenmdareceptornitricoxidecyclicgmppathwaytodevelopnondopaminergicantipsychoticmedicationsforschizophrenia
AT machadodesousajoaopaulo targetingthenmdareceptornitricoxidecyclicgmppathwaytodevelopnondopaminergicantipsychoticmedicationsforschizophrenia
AT bakerglenb targetingthenmdareceptornitricoxidecyclicgmppathwaytodevelopnondopaminergicantipsychoticmedicationsforschizophrenia
AT dursunserdar targetingthenmdareceptornitricoxidecyclicgmppathwaytodevelopnondopaminergicantipsychoticmedicationsforschizophrenia
AT hallakjaimeec targetingthenmdareceptornitricoxidecyclicgmppathwaytodevelopnondopaminergicantipsychoticmedicationsforschizophrenia
AT soaresbrunolobao aviareceptornmdaoxidonitricogmpciclicocomoalvoparaodesenvolvimentodemedicacoesantipsicoticasnaodopaminergicasparaaesquizofrenia
AT oliveirajoaopaulomaiade aviareceptornmdaoxidonitricogmpciclicocomoalvoparaodesenvolvimentodemedicacoesantipsicoticasnaodopaminergicasparaaesquizofrenia
AT machadodesousajoaopaulo aviareceptornmdaoxidonitricogmpciclicocomoalvoparaodesenvolvimentodemedicacoesantipsicoticasnaodopaminergicasparaaesquizofrenia
AT bakerglenb aviareceptornmdaoxidonitricogmpciclicocomoalvoparaodesenvolvimentodemedicacoesantipsicoticasnaodopaminergicasparaaesquizofrenia
AT dursunserdar aviareceptornmdaoxidonitricogmpciclicocomoalvoparaodesenvolvimentodemedicacoesantipsicoticasnaodopaminergicasparaaesquizofrenia
AT hallakjaimeec aviareceptornmdaoxidonitricogmpciclicocomoalvoparaodesenvolvimentodemedicacoesantipsicoticasnaodopaminergicasparaaesquizofrenia
_version_ 1773962704156884992

Registros relacionados